GlassScriptPhysician profile
Noam Zeffren
NPI 1700373750
$2,394.19
in general payments reported to CMS, 2019-2025
25 companies · $997 in 2025
The $997 reported for 2025 was more than what 89% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.00 · 2022: $59.72 · 2023: $403 · 2024: $919 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,319.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $463.08 | 2023-2025 | |
| Lilly USA, LLC | $365.87 | 2023-2025 | Kisunla, Amyvid |
| Otsuka America Pharmaceutical, INC. | $332.66 | 2023-2025 | Rexulti, Nuedexta |
| Sumitomo Pharma America, INC. | $215.95 | 2025 | Gemtesa, Myfembree |
| Abbvie INC. | $199.25 | 2023-2025 | Vraylar |
| Ge Healthcare | $160.12 | 2024-2025 | |
| Viatris Specialty LLC | $144.98 | 2025 | Yupelri |
| Exact Sciences Corporation | $77.69 | 2023-2024 | Cologuard Collection Kit |
| Lundbeck LLC | $68.88 | 2023-2025 | Rexulti |
| Pfizer INC. | $66.86 | 2023-2024 | |
| Mylan Specialty L.P. | $36.25 | 2022-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $33.99 | 2024-2025 | Capvaxive |
| C2n Diagnostics, LLC | $31.61 | 2025 | Precivityad2 |
| Tempus Ai, INC | $24.71 | 2024 | |
| Dexcom, INC. | $22.67 | 2023 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.85 | 2022 | |
| Aimmune Therapeutics, INC. | $16.77 | 2025 | Zenpep |
| Insmed, INC. | $16.07 | 2024 | Arikayce |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.83 | 2025 | Xifaxan |
| Biogen, INC. | $15.62 | 2025 | Leqembi |
| Takeda Pharmaceuticals U.S.A., INC. | $15.29 | 2023 | Vpriv |
| Glaxosmithkline, LLC. | $15.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.98 | 2024 | Austedo Xr |
| Cumberland Pharmaceuticals, INC. | $12.42 | 2022 | |
| Nestle Healthcare Nutrition INC. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noam Zeffren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.